HCA Healthcare
HCA
$410.50
+4.39%
HCA Healthcare, Inc. is the largest for-profit operator of acute-care hospitals and outpatient facilities in the United States, with a network of 190 hospitals and over 2,500 sites across 19 states and a small international presence. The company is a dominant market leader in its geographic footprint, leveraging its scale for operational efficiency, physician recruitment, and negotiating power with payers. The current investor narrative centers on the stock's significant underperformance relative to the broader market in 2026, driven by concerns over regulatory pressures, labor costs, and patient mix headwinds, juxtaposed against its historically strong cash generation and shareholder return profile, which has led to debates about whether the sell-off presents a long-term value opportunity.…
HCA
HCA Healthcare
$410.50
Related headlines
Investment Opinion: Should I buy HCA Today?
Rating & Thesis: HCA is a Hold for value-oriented, income-seeking investors, as the stock's deeply discounted valuation and high cash yield are offset by severe negative momentum and sector headwinds that warrant caution before establishing new positions. The lack of a clear analyst consensus target underscores the current uncertainty.
Supporting Evidence: The primary valuation metric, the forward P/E of 11.8x, sits at a discount to the trailing P/E of 16.3x and is in line with or below sector averages, suggesting much of the bad news is priced in. Revenue growth remains solid at 6.7% YoY, and profitability is robust with a 9.6% net margin. Most compelling is the immense free cash flow generation of $7.69B TTM, which funds a shareholder return program evidenced by $2.56B in Q4 buybacks alone.
Risks & Conditions: The biggest risks are the continued technical downtrend, leveraged balance sheet, and regulatory/labor cost pressures. This Hold rating would upgrade to a Buy if the stock stabilizes above key technical support (e.g., holds above $375) and demonstrates margin resilience in the next earnings report, or if the forward P/E compresses further toward 10x. It would downgrade to a Sell if the price breaks decisively below the 52-week low of $330 or if quarterly revenue growth decelerates below 4%. Relative to its own history and cash-generating power, the stock appears fairly valued to slightly undervalued, but it is not yet a clear bargain given the prevailing negative momentum.
Sign up to view all
HCA 12-Month Price Forecast
The AI assessment is neutral with medium confidence. HCA presents a classic value vs. momentum conflict: its cash-generating power and discounted valuation are compelling, but the severe technical breakdown and sector headwinds create near-term headwinds. The base case (60% probability) of range-bound trading between $400 and $470 is most likely, as the stock digests its recent decline. The stance would upgrade to bullish on a confirmed technical reversal above $430-$450 accompanied by stable margins, or downgrade to bearish on a break below $330 with deteriorating fundamentals. The high free cash flow yield remains the core defensive attribute for patient investors.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Healthcare's 12-month outlook, with a consensus price target around $533.65 and implied upside of +30.0% versus the current price.
Average Target
$533.65
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$328 - $534
Analyst target range
Insufficient analyst coverage data is available to provide a precise consensus target price, Buy/Hold/Sell distribution, or implied upside/downside calculation. The provided data includes analyst ratings actions but lacks the aggregated summary metrics typically used for this section. Limited or fragmented coverage can be common even for large-cap stocks like HCA when data sources are incomplete, which means market sentiment must be inferred from recent price action and institutional rating changes rather than a formal consensus. The implications of limited visible consensus data include potentially higher volatility and less efficient price discovery, as investors rely more on their own fundamental work, though HCA's size and liquidity generally ensure it is widely followed by the institutional investment community.
Bulls vs Bears: HCA Investment Factors
The evidence currently tilts bearish due to the stock's severe technical breakdown and accelerating negative momentum, which outweighs its strong fundamental cash generation. The bear case is supported by the clear downtrend, significant underperformance, and leveraged balance sheet. However, the bull case presents a compelling value argument based on robust free cash flow, a discounted forward P/E of 11.8x, and industry-leading scale. The single most important tension in the investment debate is whether HCA's formidable cash-generating ability and discounted valuation can overcome the powerful negative momentum and sector headwinds that have driven the price down 17.9% in six months. The resolution hinges on whether upcoming earnings demonstrate margin resilience against cost pressures.
Bullish
- Robust FCF and Shareholder Returns: HCA generated $7.69 billion in trailing twelve-month free cash flow, funding aggressive capital returns. In Q4 2025 alone, the company deployed $2.56 billion in buybacks and paid $162 million in dividends, demonstrating a shareholder-friendly model.
- Attractive Forward Valuation: The stock trades at a forward P/E of 11.8x, which is at a discount to its trailing P/E of 16.3x and near the lower end of its historical range. This suggests significant pessimism is already priced in relative to expected earnings growth.
- Strong and Consistent Revenue Growth: Q4 2025 revenue grew 6.7% year-over-year to $19.51 billion, continuing a trend of mid-single-digit expansion. This growth is underpinned by a diversified payer mix, reducing concentration risk.
- Industry-Leading Scale and Profitability: HCA maintains strong profitability with a Q4 2025 gross margin of 41.9% and an operating margin of 16.3%. Its network of 190 hospitals provides significant operational leverage and negotiating power.
Bearish
- Severe Price and Momentum Breakdown: HCA is in a pronounced downtrend, down 16.7% year-to-date and 17.0% over the last three months. The stock's beta of 1.134 has amplified its downside, and it has underperformed the S&P 500 by 31.96% over three months, signaling persistent institutional selling.
- Leveraged Balance Sheet Structure: The company has a debt-to-equity ratio of -8.33 and a current ratio of 0.83, indicating a highly leveraged financial structure with negative shareholder equity due to buybacks. This necessitates consistent, strong cash flow to service obligations.
- Regulatory and Labor Cost Headwinds: Recent industry news highlights headwinds like unfavorable patient insurance mix pressuring revenue. As the largest operator, HCA is highly exposed to regulatory changes and wage inflation, which could pressure its 9.6% net margin.
- Valuation Compression Despite Growth: The trailing P/E has compressed from above 20x in late 2024 to 16.3x, despite solid revenue growth. This suggests the market is discounting future earnings potential due to sector-wide concerns, potentially limiting multiple expansion.
HCA Technical Analysis
The prevailing price trend for HCA is a pronounced downtrend, with the stock down 17.9% over the past six months and 16.7% year-to-date as of June 26, 2026. The current price of $391.68 sits near the lower end of its 52-week range, trading at approximately 70% of the range from its low of $330 to its high of $556.52, indicating the stock is in a deep correction and approaching levels that may attract value-oriented buyers, though the persistent downtrend suggests significant selling pressure remains. Recent momentum shows a stark divergence from the modest 1-year gain of 3.7%, with the stock down 17.0% over the last three months and 12.0% over the past month, signaling accelerating negative momentum that has overwhelmed any longer-term resilience. This sharp short-term decline, coupled with a relative strength reading of -31.96 over three months versus the S&P 500, confirms a severe breakdown and suggests the stock is deeply oversold in the near term, though a clear reversal catalyst is not yet evident. Key technical levels are clear, with immediate support at the 52-week low of $330 and formidable resistance at the recent highs near $556.52; a sustained break below $330 would signal a continuation of the bearish trend, while a recovery above the $430-$450 zone would be needed to suggest a potential bottoming process. The stock's beta of 1.134 indicates it is approximately 13% more volatile than the broader market, which has amplified its downside during this risk-off move in the sector, a critical factor for risk management.
Beta
1.13
1.13x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$330-$557
Price range past year
Annual Return
+8.6%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | +11.7% | -1.9% |
| 3m | -13.0% | +13.6% |
| 6m | -12.7% | +9.0% |
| 1y | +8.6% | +20.0% |
| ytd | -12.7% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
HCA's revenue trajectory remains solidly positive, with Q4 2025 revenue of $19.51 billion representing a 6.7% year-over-year growth rate, continuing a trend of mid-single-digit expansion visible in sequential quarterly results. The revenue segment data shows the business is diversified across payers, with Managed Care and Other Insurers contributing $9.54 billion, Medicare at $2.85 billion, and Medicaid at $1.50 billion for the period, indicating a balanced payer mix that mitigates concentration risk, though the modest international contribution of $474 million highlights its domestic focus. This consistent top-line growth, driven by both volume and pricing, underpins the company's scale advantage in a fragmented industry. Profitability is robust, with Q4 2025 net income of $1.88 billion and a gross margin of 41.9%, reflecting the company's ability to maintain healthy margins despite industry-wide cost pressures. The operating margin for the quarter was 16.3%, and the net margin was 9.6%, demonstrating efficient cost control and high operating leverage from its large hospital network. While margins can fluctuate with patient acuity and labor costs, the company has historically sustained industry-leading profitability, which supports significant cash generation for shareholder returns. The balance sheet shows a debt-to-equity ratio of -8.33, which is an accounting artifact due to negative shareholder equity from large share buybacks, but the company's cash flow strength is undeniable, with trailing twelve-month free cash flow of $7.69 billion. This massive FCF, translating to a high FCF yield, funds aggressive capital allocation, including $2.56 billion in stock repurchases and $162 million in dividends paid in Q4 alone, showcasing a shareholder-friendly model, though the negative equity and current ratio of 0.83 indicate a leveraged financial structure that requires consistent cash flow to service.
Quarterly Revenue
$19.5B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Given HCA's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 16.3x and a forward PE of 11.8x based on estimated EPS. The significant discount of the forward multiple implies the market expects earnings growth to continue, or it reflects a depressed current price anticipating a near-term earnings rebound, creating a potential valuation gap if execution meets expectations. Compared to typical industry averages for hospital operators, which often trade in the low-to-mid teens PE range, HCA's trailing multiple is at a slight premium, justified by its market-leading scale, consistent profitability, and superior cash flow generation. However, the forward multiple of 11.8x suggests the stock is trading in line with or at a discount to its historical and sector norms, indicating much of the negative sentiment may already be priced in, assuming forward estimates are achievable. Historically, the stock's own PE ratio has fluctuated significantly; the current trailing PE of 16.3x is below the 14.3x reported at the end of Q4 2025 and well below levels above 20x seen in late 2024, placing it near the lower end of its recent historical range. This compression suggests the market has priced in significant pessimism regarding growth, margins, or regulatory risks, making the stock appear relatively cheap on its own history, though this could also signal fundamental concerns that may prevent a quick re-rating.
PE
16.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HCA operates with a leveraged financial structure, evidenced by a debt-to-equity ratio of -8.33 and a current ratio of 0.83, which indicates potential liquidity strain if operating cash flow falters. While the company generates massive free cash flow ($7.69B TTM), this cash is heavily allocated to shareholder returns, leaving the balance sheet reliant on continued operational excellence. Revenue, though growing at 6.7% YoY, faces concentration risk in the domestic U.S. market and sensitivity to patient mix shifts, as highlighted by peer Tenet Healthcare's recent sales miss, which could pressure the 9.6% net margin.
Market & Competitive Risks: The stock's valuation has compressed, with its trailing P/E of 16.3x now near the lower end of its historical range, but it remains at a slight premium to typical hospital operator multiples in the low-to-mid teens, leaving room for further de-rating if sentiment worsens. The beta of 1.134 indicates the stock is 13% more volatile than the market, amplifying downside during sector-wide risk-off moves. Competitive and regulatory pressures are persistent threats, with recent news underscoring industry headwinds from unfavorable admissions mix, which could lead to sustained margin pressure and slower growth.
Worst-Case Scenario: A worst-case scenario involves a combination of escalating labor costs, adverse regulatory changes impacting reimbursement rates, and a broader economic slowdown reducing patient volumes. This could trigger a significant earnings miss, leading to a credit rating review and forcing a reduction in the aggressive share buyback program that supports the stock. In this adverse scenario, the stock could realistically test its 52-week low of $330, representing a downside of approximately -16% from the current price of $391.68, with potential for further declines if the negative feedback loop between fundamentals and sentiment intensifies.
FAQ
The key risks are, in order of severity: 1) Financial Risk: A leveraged balance sheet with negative shareholder equity (Debt/Equity: -8.33) and a low current ratio (0.83) requires flawless execution to maintain. 2) Operational/Macro Risk: Exposure to regulatory changes and labor cost inflation, which could compress the current 9.6% net margin, as seen in recent industry commentary. 3) Market Risk: The stock's high beta of 1.134 amplifies downside in market sell-offs, and it is in a severe technical downtrend with -31.96 relative strength over three months. 4) Sentiment Risk: Limited visible analyst consensus data may contribute to higher volatility and inefficient price discovery during this period of negative sentiment.
The 12-month outlook is framed by three scenarios. The Base Case (60% probability) sees the stock trading between $400 and $470 as it consolidates, driven by steady execution, ~6.5% revenue growth, and sustained buybacks. The Bull Case (25% probability) targets $500-$556, requiring a sentiment reversal and valuation re-rating on strong margin performance. The Bear Case (15% probability) sees a retest of the 52-week low, with a range of $330-$380, triggered by margin compression and a slowdown in capital returns. The most likely outcome is the Base Case, contingent on HCA maintaining its current level of profitability amidst industry headwinds.
Based on the provided data, HCA appears fairly valued to slightly undervalued. The primary metric, the forward P/E of 11.8x, represents a significant discount to its own trailing P/E of 16.3x and is at the lower end of its recent historical range. Compared to typical hospital operator multiples in the low-to-mid teens, it is trading in line or at a slight discount. This valuation implies the market expects minimal growth or potential margin compression. The stock's price-to-sales ratio of 1.42 and EV/EBITDA of 10.05 further support a valuation that is not stretched, especially given its 6.7% revenue growth.
HCA presents a complex risk/reward profile. For value investors with a long-term horizon, the current price offers an attractive entry point into a cash-generating market leader trading at a forward P/E of 11.8x. The implied upside to a base-case target of $400-$470 is meaningful, and the high free cash flow supports shareholder returns. However, the significant near-term risks include the persistent downtrend (down 17.9% in six months), leveraged balance sheet, and sector headwinds. It is a good buy for patient, risk-tolerant investors seeking yield and value, but not for those seeking low-volatility or short-term gains.
HCA is predominantly suitable for a long-term investment horizon of 3+ years. Its high beta of 1.134 and current severe downtrend make it a poor candidate for short-term trading, as volatility could lead to significant losses. The investment thesis is based on the company's durable competitive scale, consistent cash generation, and shareholder return program, which are long-term value drivers. The stock does pay a small dividend (0.63% yield), but its primary return mechanism is share repurchases, which accrue value over time. Investors should be prepared to hold through potential further near-term volatility to realize the value offered by its discounted valuation.